Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1689607 | 1.00 | NFE2L2 (0.61) | NFE2L2PTGS1PTGS2GRIN2DGRIN3B | |
| SCHEMBL25242025 | 0.78 | TDP1 (0.42) | NFE2L2ALDH1A1 | |
| SCHEMBL2097319 | 0.78 | PTGS2 (0.42) | NFE2L2PTGS1PTGS2HTR2AKCNH2 | |
| SCHEMBL2094145 | 0.78 | GPR183 (0.39) | NFE2L2PTGS1PTGS2CYP1A1CYP1B1 | |
| SCHEMBL2097320 | 0.78 | PTGS2 (0.42) | NFE2L2PTGS1PTGS2HTR2AKCNH2 | |
| SCHEMBL2094144 | 0.78 | GPR183 (0.39) | NFE2L2PTGS1PTGS2CYP1A1CYP1B1 | |
| SCHEMBL15349281 | 0.77 | NFE2L2 (0.61) | NFE2L2PTGS1PTGS2GRIN2DGRIN3B | |
| SCHEMBL13891146 | 0.77 | NFE2L2 (0.61) | NFE2L2PTGS1PTGS2GRIN2DGRIN3B | |
| SCHEMBL15349283 | 0.77 | NFE2L2 (0.61) | NFE2L2PTGS1PTGS2GRIN2DGRIN3B | |
| SCHEMBL13790315 | 0.77 | NFE2L2 (0.96) | NFE2L2PTGS1PTGS2HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9686990-B2 | Spiroindolinepiperidine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20160007608-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-9174987-B2 | Spiroindolinepiperidine derivatives | SYNGENTA LIMITED (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-1880996-B1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20120010220-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-12 | — | — | US | disclosed |
| CN-1662535-B | Spiroindolinepiperidine derivatives | SYNGENTA LTD | 2011-09-07 | — | — | CN | disclosed |
| CN-101318958-B | Midbody for preparing spiroindolinepiperidine derivatives | SYNGENTA LTD | 2011-06-15 | — | — | CN | disclosed |
| CN-1944431-A | Spiroindolinepiperidine derivatives | SYNGENTA LTD (GB) | 2007-04-11 | — | — | CN | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060106045-A1 | Spiroindolinepiperidine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1662535-A | Spiroindolinepiperidine derivatives | SYNGENTA LTD (GB) | 2005-08-31 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-5053070-A | PYRIMIDINE DERIVATIVES, PREPARATION PROCESSES THEREOF, HERBICIDE CONTAINING THE SAME, AND HERBICIDAL COMPOSITIONS CONTAINING THE SAME ALONG WITH OTHER ACTIVE INGREDIENT | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-10-01 | — | — | US | disclosed |
| US-4986846-A | PRE-AND POSTEMERGENCE | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0374839-A1 | 2-(4,6-Dimethoxy-2-pyrimidinyloxy)benzaldoximes, preparation processes thereof, herbicides containing the same, and herbicidal compositions containing the same along with other active ingredients | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | NFE2L2 846/4885PTGS1 3838/4885PTGS2 3418/4885 |
| US-20120010220-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | RECQL, OPRD1, SKP1 | NFE2L2 693/4885PTGS1 1137/4885PTGS2 1367/4885 |
| US-20060106045-A1 | Spiroindolinepiperidine derivatives | RECQL, OPRD1, NCAPD3 | NFE2L2 681/4885PTGS1 1127/4885PTGS2 1342/4885 |
| US-20160007608-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | RECQL, OPRD1, SKP1 | NFE2L2 693/4885PTGS1 1137/4885PTGS2 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.